About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Mirabegron

Company: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 16 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

16 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Recruiting NCT NCT04666636

Mechanisms for Activation of Beige Adipose Tissue in Humans

Not yet reported Philip Kern 65 participants Est. completion 2027-12 1 site Stand-alone

Prediabetes
View official trial listing →
Recruiting NCT NCT05051436

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

Not yet reported Philip Kern 96 participants Est. completion 2027-01 1 site Stand-alone

Prediabetes Other conditions: Obesity
View official trial listing →
Recruiting NCT NCT05221021

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Not yet reported Walter Reed National Military Medical Center 152 participants Est. completion 2027-01-30 1 site

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Recruiting NCT NCT05362292

TReating Incontinence for Underlying Mental and Physical Health

Not yet reported University of California, San Francisco 270 participants Est. completion 2027-08-02 2 sites

Other conditions: Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder, Incontinence, Urge, Incontinence, Urinary, Incontinence
View official trial listing →
Recruiting NCT NCT05369351

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Not yet reported Tianjin Medical University General Hospital 25 participants Est. completion 2026-11-10 1 site Stand-alone

Other conditions: Intracerebral Haemorrhage
View official trial listing →
Recruiting NCT NCT05968885

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Not yet reported Mackay Memorial Hospital 300 participants Est. completion 2026-12-31 1 site Stand-alone

Other conditions: Urinary Bladder, Overactive, Urodynamics, Effect of Drug
View official trial listing →
Recruiting NCT NCT06197295

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Not yet reported Mackay Memorial Hospital 200 participants Est. completion 2026-12-31 1 site

Other conditions: Urinary Bladder, Overactive, Effect of Drug
View official trial listing →
Recruiting NCT NCT06479720

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Not yet reported Mackay Memorial Hospital 300 participants Est. completion 2026-12-31 1 site Stand-alone

Other conditions: Effect of Drug, Urinary Bladder, Overactive
View official trial listing →
Recruiting NCT NCT06534762

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Not yet reported Zhejiang Provincial People's Hospital 260 participants Est. completion 2028-07-01 1 site Stand-alone

Other conditions: NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer, TNBC - Triple-Negative Breast Cancer, DLBCL - Diffuse Large B Cell Lymphoma, Squamous Cell Carcinoma of Head and Neck
View official trial listing →
Recruiting NCT NCT06551246

Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)

Not yet reported University of Aarhus 236 participants Est. completion 2027-12-01 5 sites Stand-alone

Other conditions: Urinary Incontinence in Children
View official trial listing →
Recruiting NCT NCT06791460

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Not yet reported, Not yet reported Obstetrics & Gynecology Hospital of Fudan University 296 participants Est. completion 2030-02-14 1 site Stand-alone

Other conditions: Ovarian Cancer Recurrent
View official trial listing →
Recruiting NCT NCT06803030

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Not yet reported Bir Hospital 189 participants Est. completion 2026-12-31 1 site

Other conditions: Ureteral Stent-Related Symptom
View official trial listing →
Recruiting NCT NCT07025642

Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes

Not yet reported Mackay Medical College 60 participants Est. completion 2026-12-01 1 site Stand-alone

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Recruiting NCT NCT07199894

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

Not yet reported Mansoura University 120 participants Est. completion 2026-02-01 1 site Stand-alone

Other conditions: Nocturnal Enuresis in Children
View official trial listing →
Recruiting NCT NCT07261683

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

Not yet reported Obstetrics & Gynecology Hospital of Fudan University 20 participants Est. completion 2028-11-30 1 site Stand-alone

Other conditions: Ovarian Cancer, Immunotherapy, Pembrolizumab
View official trial listing →
Recruiting NCT NCT07310797

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

Not yet reported Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 500 participants Est. completion 2030-12-31 1 site Stand-alone

Other conditions: Ureteral Calculi
View official trial listing →
Completed NCT NCT00337090

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Not yet reported Astellas Pharma Inc 1108 participants Est. completion 2007-03 84 sites

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT00410514

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Not yet reported Astellas Pharma Inc 200 participants Est. completion 2008-08 27 sites Stand-alone

Other conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
View official trial listing →
Completed NCT NCT00527033

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Not yet reported Astellas Pharma Inc 842 participants Est. completion 2008-04-03 5 sites

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00662909

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Inc 2149 participants Est. completion 2009-04-22 125 sites Stand-alone

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00688688

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Inc 2792 participants Est. completion 2010-05-06 308 sites Stand-alone

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00689104

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Inc 2336 participants Est. completion 2009-03-24 218 sites Stand-alone

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00750620

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Not yet reported Astellas Pharma Inc 33 participants Est. completion 2009-09 2 sites

Other conditions: Renal Impairment
View official trial listing →
Completed NCT NCT00776516

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

Not yet reported Astellas Pharma Inc 24 participants Est. completion 2008-12 1 site Stand-alone

Other conditions: Pharmacokinetics of YM178
View official trial listing →
Completed NCT NCT00840645

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

Not yet reported Astellas Pharma Inc 204 participants Est. completion 2010-03 2 sites

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00856570

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Not yet reported Astellas Pharma Inc 24 participants Est. completion 2008-12 1 site

Other conditions: Overactive Bladder, Pharmacokinetics
View official trial listing →
Completed NCT NCT00912964

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Inc 2030 participants Est. completion 2010-04-27 151 sites Stand-alone

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT00939757

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Not yet reported Astellas Pharma Inc 76 participants Est. completion 2009-07 1 site Stand-alone

Other conditions: Healthy, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT00940121

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Not yet reported Astellas Pharma Inc 91 participants Est. completion 2009-07-13 1 site Stand-alone

Other conditions: Healthy, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT00965926

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Not yet reported Astellas Pharma Inc 72 participants Est. completion 2009-09 1 site

Other conditions: Healthy Volunteer, Pharmacokinetics of YM178
View official trial listing →
Completed NCT NCT00966004

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Not yet reported Astellas Pharma Inc 1139 participants Est. completion 2010-02-15 4 sites

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT01043666

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Inc 1126 participants Est. completion 2011-09-16 35 sites

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT01199523

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

Not yet reported Astellas Pharma Inc 352 participants Est. completion 2010-11 2 sites Stand-alone

Other conditions: Healthy Subjects
View official trial listing →
Completed NCT NCT01284309

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Not yet reported Astellas Pharma Inc 321 participants Est. completion 2011-02 2 sites Stand-alone

Other conditions: Intraocular Pressure
View official trial listing →
Completed NCT NCT01284868

A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.

Not yet reported Astellas Pharma Inc 12 participants Est. completion 2009-11 1 site Stand-alone

Other conditions: Healthy Volunteers, Pharmacodynamics of Mirabegron
View official trial listing →
Completed NCT NCT01285596

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Not yet reported Astellas Pharma Inc 75 participants Est. completion 2009-11 1 site

Other conditions: Healthy Volunteers, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT01297179

A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill

Not yet reported Astellas Pharma Inc 30 participants Est. completion 2009-03 1 site

Other conditions: Healthy Volunteers, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT01297192

A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

Not yet reported Astellas Pharma Inc 41 participants Est. completion 2009-07 1 site

Other conditions: Healthy Volunteers, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT01334905

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Not yet reported Astellas Pharma Inc 12 participants Est. completion 2011-06 1 site

Other conditions: Healthy Volunteer, Pharmacokinetics of YM178
View official trial listing →
Completed NCT NCT01340027

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

Not yet reported Astellas Pharma Europe B.V. 1307 participants Est. completion 2012-06-28 133 sites Stand-alone

Other conditions: Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms, Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT01476800

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

Not yet reported Astellas Pharma Inc 24 participants Est. completion 2006-11 1 site

Other conditions: Healthy Subjects, Pharmacokinetics of YM178
View official trial listing →
Completed NCT NCT01478490

To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol

Not yet reported Astellas Pharma Inc 28 participants Est. completion 2002-11 1 site Stand-alone

Other conditions: Pharmacokinetics of Mirabegron, Healthy Subjects
View official trial listing →
Completed NCT NCT01478503

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Not yet reported Astellas Pharma Inc 96 participants Est. completion 2005-10 2 sites Stand-alone

Other conditions: Pharmacokinetics, Healthy Subjects
View official trial listing →
Completed NCT NCT01478529

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Not yet reported Astellas Pharma Inc 12 participants Est. completion 2006-03 1 site Stand-alone

Other conditions: Pharmacokinetics of Mirabegron, Bioavailability, Healthy Subjects
View official trial listing →
Completed NCT NCT01478568

To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together

Not yet reported Astellas Pharma Inc 28 participants Est. completion 2009-01 1 site Stand-alone

Other conditions: Pharmacokinetics of Mirabegron, Healthy Subjects
View official trial listing →
Completed NCT NCT01489696

A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin

Not yet reported Astellas Pharma Inc 48 participants Est. completion 2011-02 1 site Stand-alone

Other conditions: Cardiovascular, Healthy Subjects, Pharmacokinetics
View official trial listing →
Completed NCT NCT01579461

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Not yet reported Astellas Pharma Europe B.V. 32 participants Est. completion 2009-04 1 site Stand-alone

Other conditions: Pharmacokinetics, Healthy Subjects, Mild and Moderate Hepatic Impairment
View official trial listing →
Completed NCT NCT01604928

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Europe B.V. 260 participants Est. completion 2005-01-25 30 sites

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Completed NCT NCT01638000

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

Not yet reported Astellas Pharma Europe Ltd. 1887 participants Est. completion 2013-04-24 217 sites Stand-alone

Other conditions: Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
View official trial listing →
Completed NCT NCT01646294

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Not yet reported Astellas Pharma Europe B.V. 34 participants Est. completion 2005-05 1 site

Other conditions: Pharmacokinetics of YM178, Healthy Subjects
View official trial listing →
Completed NCT NCT01651312

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Not yet reported Astellas Pharma Europe B.V. 4 participants Est. completion 2003-02 1 site

Other conditions: Metabolic Processes
View official trial listing →
Completed NCT NCT01663961

A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178

Not yet reported Astellas Pharma Europe B.V. 25 participants Est. completion 2008-12 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT01720212

Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

Not yet reported Astellas Pharma China, Inc. 24 participants Est. completion 2012-08 1 site

Other conditions: Healthy Chinese Volunteers
View official trial listing →
Completed NCT NCT01745094

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Not yet reported Astellas Pharma Inc 223 participants Est. completion 2013-07-23 5 sites Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT01747564

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Not yet reported Astellas Pharma Inc 24 participants Est. completion 2012-10 1 site Stand-alone

Other conditions: Healthy Subjects, Plasma Concentration of Mirabegron
View official trial listing →
Completed NCT NCT01783470

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Not yet reported Aaron Cypess 15 participants Est. completion 2014-10 1 site

Other conditions: Obesity
View official trial listing →
Completed NCT NCT01876433

Beta 3 Agonist Treatment in Heart Failure

Not yet reported Henning Bundgaard 70 participants Est. completion 2015-09-30 3 sites

Heart failure
View official trial listing →
Completed NCT NCT01898624

Specified Drug Use-results Survey of Betanis Tablets

Astellas Pharma Inc 300 participants Est. completion 2018-01-10 7 sites

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT01901120

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Astellas Pharma Inc 1263 participants Est. completion 2016-09 8 sites

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT01908829

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Not yet reported Astellas Pharma Europe Ltd. 2174 participants Est. completion 2014-11-25 219 sites Stand-alone

Other conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
View official trial listing →
Completed NCT NCT01919047

Drug Use-Results Survey of Betanis Tablets in Japan

Astellas Pharma Inc 10711 participants Est. completion 2014-07 8 sites

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT01950520

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 47 participants Est. completion 2024-06-11 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Completed NCT NCT01964183

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine

Not yet reported Astellas Pharma Inc 24 participants Est. completion 2013-08 1 site Stand-alone

Other conditions: Pharmacokinetics of Mirabegron and Tolterodine, Healthy
View official trial listing →
Completed NCT NCT01972841

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Europe B.V. 3527 participants Est. completion 2015-10-22 435 sites Stand-alone

Other conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
View official trial listing →
Completed NCT NCT02010944

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Not yet reported Astellas Pharma Europe B.V. 72 participants Est. completion 2012-11 1 site Stand-alone

Other conditions: Phase 1, Bioavailability, Healthy Subjects
View official trial listing →
Terminated NCT NCT02044510

Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients

Not yet reported, Not yet reported London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 32 participants Est. completion 2018-02 5 sites Stand-alone

Other conditions: Urinary Bladder, Neurogenic
View official trial listing →
Completed NCT NCT02045862

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Not yet reported Astellas Pharma Europe B.V. 1829 participants Est. completion 2016-09-08 251 sites Stand-alone

Other conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
View official trial listing →
Completed NCT NCT02086188

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

Not yet reported Theodore R. Brown, MD MPH 28 participants Est. completion 2019-06 1 site Stand-alone

Other conditions: Multiple Sclerosis
View official trial listing →
Completed NCT NCT02092181

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)

Not yet reported Daniel Burdick, MD 30 participants Est. completion 2018-07-01 1 site

Other conditions: Parkinsons Disease
View official trial listing →
Completed NCT NCT02095665

Ureteral Stent-related Pain and Mirabegron (SPAM) Trial

Not yet reported Nova Scotia Health Authority 22 participants Est. completion 2018-03-23 1 site Stand-alone

Other conditions: Nephrolithiasis
View official trial listing →
Completed NCT NCT02127034

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Not yet reported Astellas Pharma Europe B.V. 26 participants Est. completion 2014-06 1 site Stand-alone

Other conditions: Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)
View official trial listing →
Completed NCT NCT02138747

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Not yet reported Astellas Pharma Global Development, Inc. 376 participants Est. completion 2015-11-11 30 sites Stand-alone

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Completed NCT NCT02169713

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Not yet reported Astellas Pharma Europe B.V. 20 participants Est. completion 2014-08 1 site Stand-alone

Other conditions: Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)
View official trial listing →
Completed NCT NCT02211846

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Not yet reported Astellas Pharma Inc 34 participants Est. completion 2015-09-21 13 sites Stand-alone

Other conditions: Neurogenic Detrusor Overactivity, Overactive Bladder, Pharmacokinetics of Mirabegron
View official trial listing →
Completed NCT NCT02216214

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Not yet reported Astellas Pharma Global Development, Inc. 888 participants Est. completion 2018-01-02 120 sites Stand-alone

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Status unknown NCT NCT02279615

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Not yet reported St. Joseph's Healthcare Hamilton 200 participants Est. completion 2022-12 1 site

Other conditions: Overactive Bladder, Benign Prostatic Hyperplasia
View official trial listing →
Completed NCT NCT02294396

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Not yet reported Astellas Pharma Inc 649 participants Est. completion 2016-09-07 7 sites Stand-alone

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Completed NCT NCT02311569

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Not yet reported Swiss Cancer Institute 39 participants Est. completion 2016-12 11 sites Stand-alone

Other conditions: Myeloproliferative Neoplasm, Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
View official trial listing →
Completed NCT NCT02320773

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Astellas Pharma Europe Ltd. 863 participants Est. completion 2016-07-27 60 sites

Other conditions: Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder, Urologic Diseases, Urinary Bladder Diseases
View official trial listing →
Status unknown NCT NCT02354807

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults

Not yet reported Otto Muzik 20 participants Est. completion 2018-03 1 site Stand-alone

Other conditions: Brown Fat
View official trial listing →
Status unknown NCT NCT02361502

MIrabegron With oveRACtive bLadder Symptoms in mEn

Not yet reported Seoul National University Hospital 462 participants 15 sites Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02386072

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

Astellas Scientific & Medical Affairs, Inc. 1524 participants Est. completion 2017-08-04 92 sites

Other conditions: Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
View official trial listing →
Completed NCT NCT02410135

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

Southern Illinois University 34 participants Est. completion 2018-12 1 site

Other conditions: Lower Urinary Tract Symptoms, Nocturia
View official trial listing →
Completed NCT NCT02436889

Treatment of Incontinence Without Memory Problems

Not yet reported University of California, San Francisco 23 participants Est. completion 2018-07 1 site Stand-alone

Other conditions: Urge Incontinence, Urinary Incontinence, Urge
View official trial listing →
Terminated NCT NCT02462837

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Not yet reported Southern Illinois University 11 participants Est. completion 2019-01-30 1 site Stand-alone

Other conditions: Urinary Bladder, Overactive, Pain, Lower Urinary Tract Symptoms
View official trial listing →
Completed NCT NCT02468375

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Not yet reported Samsung Medical Center 434 participants Est. completion 2017-12 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02468830

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder

Not yet reported CHU de Quebec-Universite Laval 58 participants Est. completion 2016-03 Stand-alone

Other conditions: Overactive Bladder, Urinary Incontinence
View official trial listing →
Completed NCT NCT02476175

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder

Not yet reported CHU de Quebec-Universite Laval 35 participants Est. completion 2016-06 Stand-alone

Other conditions: Overactive Bladder, Urinary Incontinence
View official trial listing →
Completed NCT NCT02495389

Mirabegron and Urinary Urgency Incontinence

Not yet reported Loyola University 84 participants Est. completion 2019-01-29 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02526979

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Not yet reported Astellas Pharma Europe B.V. 9 participants Est. completion 2016-09-30 3 sites Stand-alone

Other conditions: Overactive Bladder, Neurogenic Detrusor Overactivity
View official trial listing →
Completed NCT NCT02536976

Mirabegron in Parkinson Disease and Impaired Cognition

Not yet reported HealthPartners Institute 7 participants Est. completion 2018-08-01 1 site Stand-alone

Other conditions: Parkinson Disease, Overactive Bladder, Impaired Cognition
View official trial listing →
Completed NCT NCT02540707

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Not yet reported National Taiwan University Hospital 113 participants Est. completion 2020-08-26 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT02570035

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Astellas Pharma Inc 316 participants Est. completion 2015-03 28 sites

Cardiovascular disease Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02599480

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

Not yet reported Jean-Luc Balligand 296 participants Est. completion 2022-02-16 10 sites

Other conditions: Hypertrophy, Left Ventricular
View official trial listing →
Completed NCT NCT02622555

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

Karolinska Institutet 221 participants Est. completion 2015-11 1 site

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02656173

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

Not yet reported Astellas Pharma Inc 568 participants Est. completion 2017-07-21 58 sites Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT02744430

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Not yet reported Baylor College of Medicine 33 participants Est. completion 2019-10-31 1 site

Other conditions: Ureteral Obstruction, Flank Pain
View official trial listing →
Completed NCT NCT02751931

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Not yet reported Astellas Pharma Europe B.V. 91 participants Est. completion 2019-05-06 32 sites Stand-alone

Other conditions: Neurogenic Detrusor Overactivity
View official trial listing →
Completed NCT NCT02757768

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Not yet reported Astellas Pharma Global Development, Inc. 715 participants Est. completion 2018-09-11 79 sites Stand-alone

Other conditions: Benign Prostatic Hyperplasia, Overactive Bladder
View official trial listing →
Status unknown NCT NCT02775539

Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

Not yet reported Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III 80 participants Est. completion 2019-06

Heart failure Other conditions: Pulmonary Hypertension, Mirabegron, Pulmonary Vascular Resistance Abnormality
View official trial listing →
Terminated NCT NCT02787083

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis

Not yet reported Philadelphia Urosurgical Associates 9 participants Est. completion 2019-07-05 1 site Stand-alone

Other conditions: Cystitis, Interstitial
View official trial listing →
Completed NCT NCT02811289

Pharmacological Activation of Brown Adipose Tissue Metabolism

Not yet reported Université de Sherbrooke 22 participants Est. completion 2018-07-05 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT02893553

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

Not yet reported James J. Peters Veterans Affairs Medical Center 21 participants Est. completion 2021-12 2 sites Stand-alone

Other conditions: Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Autonomic Integrity, Hypotensive, Cognitive Function, Cerebral Blood Flow, Blood Pressure
View official trial listing →
Completed NCT NCT02916693

Mirabegron For Erectile Dysfunction

Not yet reported, Not yet reported Johns Hopkins University 20 participants Est. completion 2020-01-01 1 site Stand-alone

Other conditions: Erectile Dysfunction, Overactive Bladder, Urinary Incontinence
View official trial listing →
Completed NCT NCT02919176

Brown Fat Activation Study

Not yet reported Philip Kern 39 participants Est. completion 2019-02-04 1 site Stand-alone

Metabolic syndrome Other conditions: Obese
View official trial listing →
Withdrawn NCT NCT02981459

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Not yet reported State University of New York at Buffalo Est. completion 2018-06 1 site Stand-alone

Other conditions: Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
View official trial listing →
Status unknown NCT NCT03012113

Mirabegron and Brown Adipose Tissue

Not yet reported Ingrid Jazet 20 participants Est. completion 2017-09 1 site

Other conditions: Obesity
View official trial listing →
Status unknown NCT NCT03044912

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Not yet reported Buddhist Tzu Chi General Hospital 574 participants Est. completion 2019-08-01 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT03049462

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 55 participants Est. completion 2026-08-26 1 site Stand-alone

Other conditions: Polycystic Ovary Syndrome
View official trial listing →
Completed NCT NCT03059134

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Not yet reported Buddhist Tzu Chi General Hospital 168 participants Est. completion 2016-04-27 Stand-alone

Other conditions: Urinary Incontinence, Overactive Bladder Syndrome
View official trial listing →
Withdrawn NCT NCT03087578

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Not yet reported University Hospitals Cleveland Medical Center Est. completion 2018-09-30 1 site

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT03106623

Study of ONO-8577 in Patients With Overactive Bladder

Not yet reported Ono Pharmaceutical Co., Ltd. 207 participants Est. completion 2017-09-26 30 sites

Other conditions: Overactive Bladder
View official trial listing →
Status unknown NCT NCT03187795

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

Not yet reported Kessler Foundation 62 participants Est. completion 2022-03-30 1 site Stand-alone

Other conditions: Spinal Cord Injuries, Urinary Bladder, Neurogenic
View official trial listing →
Status unknown NCT NCT03251300

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Not yet reported Far Eastern Memorial Hospital 120 participants Est. completion 2024-12-31 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Terminated NCT NCT03411252

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Not yet reported Thomas Jefferson University 5 participants Est. completion 2019-12-15 1 site Stand-alone

Other conditions: Achalasia
View official trial listing →
Status unknown NCT NCT03412513

Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease

Not yet reported Seoul National University Hospital 144 participants Est. completion 2018-12-31 5 sites

Other conditions: Overactive Bladder, Parkinson Disease
View official trial listing →
Completed NCT NCT03536494

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Not yet reported Catalan Institute of Health 1932 participants Est. completion 2017-12-31 Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT03558919

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Not yet reported Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 81 participants Est. completion 2017-12-30 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT03572231

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Astellas Pharma Singapore Pte. Ltd. 805 participants Est. completion 2020-03-30 15 sites

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Status unknown NCT NCT03600766

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Not yet reported Mansoura University 50 participants Est. completion 2020-01-01 1 site

Other conditions: BPH, Erectile Dysfunction, Prostate Hyperplasia, Erectile Abnormalities, Prostatic Neoplasms
View official trial listing →
Completed NCT NCT03602508

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Astellas Pharma Singapore Pte. Ltd. 5589 participants Est. completion 2019-09-13 2 sites

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Completed NCT NCT03612401

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron

Not yet reported The University of Texas Health Science Center at San Antonio 20 participants Est. completion 2021-03-31 1 site

Other conditions: Spinal Cord Injuries, Neurogenic Bladder, Cognitive Change
View official trial listing →
Status unknown NCT NCT03632772

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Not yet reported Buddhist Tzu Chi General Hospital 130 participants Est. completion 2019-07-31 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Withdrawn NCT NCT03695822

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Not yet reported Far Eastern Memorial Hospital Est. completion 2019-01-31 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT03817931

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Not yet reported Baylor Research Institute 12 participants Est. completion 2022-02-26 2 sites

Other conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
View official trial listing →
Completed NCT NCT03926754

Beta 3 Agonist Treatment in Heart Failure-2

Not yet reported, Not yet reported Henning Bundgaard 56 participants Est. completion 2021-01-21 1 site

Heart failure
View official trial listing →
Status unknown NCT NCT04023253

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Not yet reported Far Eastern Memorial Hospital 120 participants Est. completion 2024-12-31 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Status unknown NCT NCT04286152

Mirabegron And Ureteral Stent-related Pain (MAP) Trial

Not yet reported Unity Health Toronto 142 participants Est. completion 2021-06-30 1 site Stand-alone

Other conditions: Nephrolithiasis
View official trial listing →
Status unknown NCT NCT04325880

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Not yet reported Mansoura University 240 participants Est. completion 2022-07-01 1 site

Other conditions: Ureteral Stent, Stent Related Symptoms
View official trial listing →
Completed NCT NCT04420533

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Not yet reported Chang Gung Memorial Hospital 150 participants Est. completion 2022-08-31 1 site Stand-alone

Other conditions: Urinary Bladder, Overactive, Sexual Behavior, Sexual Activity, Behavior Therapy, Sexual Function Disturbances
View official trial listing →
Completed NCT NCT04476966

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Not yet reported Genuine Research Center, Egypt 29 participants Est. completion 2020-05-11 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT04485585

A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

Not yet reported Boryung Pharmaceutical Co., Ltd 36 participants Est. completion 2020-08-26 1 site Stand-alone

Other conditions: Benign Prostatic Hyperplasia (BPH), Overactive Bladder
View official trial listing →
Completed NCT NCT04501640

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Not yet reported Astellas Pharma China, Inc. 24 participants Est. completion 2020-10-27 1 site Stand-alone

Other conditions: Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects
View official trial listing →
Status unknown NCT NCT04503850

Impact of Mirabegron on Erectile Function in BPH Patients

Kasr El Aini Hospital 100 participants Est. completion 2021-10-01

Other conditions: Males With Benign Prostatic Hyperplasia Symptoms
View official trial listing →
Status unknown NCT NCT04511273

Does Mirabegron Have a Positive Impact on Sexual Function in Females With Overactive Bladder

Kasr El Aini Hospital 80 participants Est. completion 2021-04-01

Other conditions: Females With Overactive Bladder Symptoms, Urgency & Urge Incontinence
View official trial listing →
Completed NCT NCT04550702

Predictors for Retreatement of OAB After DC Mirabegron

National Taiwan University Hospital 120 participants Est. completion 2019-07-31 1 site

Other conditions: Recurrence of Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT04562090

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Not yet reported Astellas Pharma China, Inc. 249 participants Est. completion 2022-03-30 15 sites Stand-alone

Other conditions: Urge Incontinence, Overactive Bladder (OAB)
View official trial listing →
Terminated NCT NCT04641975

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

Not yet reported Astellas Pharma Global Development, Inc. 26 participants Est. completion 2023-07-24 15 sites Stand-alone

Other conditions: Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
View official trial listing →
Status unknown NCT NCT04693897

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Chang Gung Memorial Hospital 400 participants Est. completion 2022-12-31

Other conditions: Overactive Bladder Syndrome, Detrusor Overactivity
View official trial listing →
Completed NCT NCT04766021

Mirabegron and Physiological Function in Cold Environments

Not yet reported, Not yet reported Indiana University 30 participants Est. completion 2023-04-27 1 site Stand-alone

Other conditions: Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue
View official trial listing →
Completed NCT NCT04823442

Activation of Brown Adipose Tissue Metabolism Using Mirabegron

Not yet reported Université de Sherbrooke 9 participants Est. completion 2022-04-04 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Completed NCT NCT04907032

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

Not yet reported University of Alabama at Birmingham 54 participants Est. completion 2023-04-15 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Status unknown NCT NCT04909255

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Not yet reported China Medical University Hospital 50 participants Est. completion 2022-08-15 1 site Stand-alone

Other conditions: Sjogren's Syndrome, Overactive Bladder Syndrome
View official trial listing →
Status unknown NCT NCT05040984

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Far Eastern Memorial Hospital 500 participants Est. completion 2024-12-31 1 site

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT05067478

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Urovant Sciences GmbH 403 participants Est. completion 2024-07-26 64 sites

Other conditions: Overactive Bladder
View official trial listing →
Status unknown NCT NCT05188742

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Not yet reported Taipei Veterans General Hospital, Taiwan 180 participants Est. completion 2023-09 1 site Stand-alone

Other conditions: Overactive Bladder Syndrome
View official trial listing →
Status unknown NCT NCT05240456

Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children

Not yet reported, Not yet reported Mansoura University 70 participants Est. completion 2022-12 Stand-alone

Other conditions: Voiding Disorders, Overactive Bladder
View official trial listing →
Status unknown NCT NCT05416450

The Efficacy of Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder

Not yet reported Pamukkale University 48 participants Est. completion 2023-01-05 1 site

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Status unknown NCT NCT05452434

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Not yet reported Peking Union Medical College Hospital 600 participants Est. completion 2023-07-15 Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Status unknown NCT NCT05490082

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Not yet reported Mansoura University 100 participants Est. completion 2023-10 1 site

Other conditions: Voiding Disorders
View official trial listing →
Active, not recruiting NCT NCT05604222

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

Not yet reported Shachi Tyagi 120 participants Est. completion 2027-03-31 1 site Stand-alone

Other conditions: Urgency Urinary Incontinence, Nocturia
View official trial listing →
Status unknown NCT NCT05617664

Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Not yet reported Benha University 150 participants Est. completion 2023-10 1 site

Other conditions: Nocturnal Enuresis
View official trial listing →
Active, not recruiting NCT NCT05621616

A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity

Not yet reported Astellas Pharma Global Development, Inc. 7 participants Est. completion 2026-09-30 3 sites Stand-alone

Other conditions: Neurogenic Detrusor Overactivity
View official trial listing →
Active, not recruiting NCT NCT05634174

ADRB3 Signaling Pathway in Human Adipose Tissue

Not yet reported University of California, San Diego 40 participants Est. completion 2025-12-31 1 site Stand-alone

Prediabetes
View official trial listing →
Terminated NCT NCT05658874

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Not yet reported Jocelyn Fitzgerald 26 participants Est. completion 2025-12-30 1 site Stand-alone

Other conditions: Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
View official trial listing →
Status unknown NCT NCT05668715

Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder

Not yet reported Pamukkale University 40 participants Est. completion 2023-06-30 1 site Stand-alone

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Not yet recruiting NCT NCT05713799

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 60 participants Est. completion 2030-03-01 1 site Stand-alone

Other conditions: Insulin Resistance, Obesity
View official trial listing →
Status unknown NCT NCT05745584

Effect of Mirabegron on Bladder Compliance

Not yet reported Yonsei University 15 participants Est. completion 2023-03-02 1 site Stand-alone

Other conditions: Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics
View official trial listing →
Completed NCT NCT05767632

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Not yet reported Genuine Research Center, Egypt 30 participants Est. completion 2022-10-25 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Status unknown NCT NCT05779514

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Not yet reported Zhejiang Provincial People's Hospital 20 participants Est. completion 2023-12-31 1 site Stand-alone

Other conditions: Tumour
View official trial listing →
Active, not recruiting NCT NCT05806164

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Not yet reported Women and Infants Hospital of Rhode Island 432 participants Est. completion 2030-08-01 5 sites

Other conditions: Urgency Urinary Incontinence
View official trial listing →
Completed NCT NCT05880862

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Not yet reported The University of Texas Medical Branch, Galveston 48 participants Est. completion 2025-12-27 1 site

Other conditions: Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
View official trial listing →
Status unknown NCT NCT05946902

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Not yet reported Far Eastern Memorial Hospital 150 participants Est. completion 2024-07-31 1 site Stand-alone

Other conditions: Female Patients With Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT05990387

MIrabegron and Physiological Function in Cold Environments

Not yet reported, Not yet reported Indiana University 17 participants Est. completion 2024-04-23 1 site Stand-alone

Other conditions: Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue
View official trial listing →
Completed NCT NCT05992428

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Not yet reported Dong-A ST Co., Ltd. 37 participants Est. completion 2023-12-05 1 site Stand-alone

Other conditions: Healthy
View official trial listing →
Completed NCT NCT06011265

Does Mirabegron Increase the Body Heat Generated by the Nervous System

Not yet reported Christopher Bell 19 participants Est. completion 2024-04-30 1 site Stand-alone

Other conditions: Thermoregulation
View official trial listing →
Active, not recruiting NCT NCT06110975

Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)

Not yet reported Anne Estrup Olesen 72 participants Est. completion 2026-12-01 1 site Stand-alone

Other conditions: Overactive Bladder, Deprescribing, PIMS
View official trial listing →
Completed NCT NCT06123364

Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder

Not yet reported Serdinsek Tamara 56 participants Est. completion 2023-10-01 1 site

Other conditions: Overactive Bladder, Overactive Bladder Syndrome
View official trial listing →
Completed NCT NCT06124066

THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS

Not yet reported Hasanuddin University 42 participants Est. completion 2022-10-30 1 site

Other conditions: Ureteral Stone, Kidney Stones, Ureteral Stenosis
View official trial listing →
Completed NCT NCT06133075

Using Mirabegron to Increase BP in Patients With POTS

Not yet reported Cedars-Sinai Medical Center 20 participants Est. completion 2025-07-25 1 site

Other conditions: Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
View official trial listing →
Status unknown NCT NCT06181019

Acupuncture Combined With Mirabegron in the Treatment of OAB

Not yet reported The Affiliated Ganzhou Hospital of Nanchang University 75 participants Est. completion 2024-12-31 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Status unknown NCT NCT06181591

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Not yet reported Seoul National University Hospital 44 participants Est. completion 2025-04-15 1 site Stand-alone

Other conditions: Overactive Bladder
View official trial listing →
Completed NCT NCT06184334

Management of OAB in Female Patients .

Not yet reported Elsayed Abdelhalim Elsayed 300 participants Est. completion 2023-12-01 1 site

Other conditions: Overactive Bladder
View official trial listing →
Active, not recruiting NCT NCT06465576

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Not yet reported University of Aarhus 216 participants Est. completion 2027-12-01 5 sites Stand-alone

Other conditions: Urinary Incontinence in Children
View official trial listing →
Completed NCT NCT07016451

Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis

Not yet reported Thanakrit Visuthikosol 25 participants Est. completion 2026-03-31 1 site Stand-alone

Other conditions: Radiation Cystitis
View official trial listing →
Not yet recruiting NCT NCT07017439

Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

Not yet reported University of Manitoba 50 participants Est. completion 2026-06 1 site Stand-alone

Other conditions: Benign Prostate Hypertrophy(BPH)
View official trial listing →
Completed NCT NCT07018934

Alfuzosin and Mirabegron for Double-J Stent Symptoms

University of Gaziantep 100 participants Est. completion 2025-05-01 1 site

Other conditions: Ureteral Stent-Related Symptoms
View official trial listing →
Not yet recruiting NCT NCT07114640

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Not yet reported Far Eastern Memorial Hospital 220 participants Est. completion 2028-12-31 1 site

Other conditions: Urinary Bladder, Overactive
View official trial listing →
Not yet recruiting NCT NCT07187466

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

Not yet reported VA Office of Research and Development 146 participants Est. completion 2030-06-30 3 sites

Other conditions: Overactive Bladder, Parkinson Disease
View official trial listing →
Active, not recruiting NCT NCT07259148

Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority Trial

Not yet reported Emilio José Dávila Álvarez 80 participants Est. completion 2026-04 1 site

Other conditions: Urgency Urinary Incontinence
View official trial listing →
Not yet recruiting NCT NCT07305298

Mirabegron in Patients With Age-Related Macular Degeneration

University of Naples 312 participants Est. completion 2026-12-01 1 site

Other conditions: Dry AMD, Overactive Bladder
View official trial listing →
Completed NCT NCT07307261

Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms

Not yet reported Avraiem Talaat 300 participants Est. completion 2025-10-10 1 site

Other conditions: Ureteric Stent-related Morbidity
View official trial listing →
Completed NCT NCT07337252

Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

Mackay Memorial Hospital 61 participants Est. completion 2024-08-31 1 site

Other conditions: Overactive Bladder
View official trial listing →
Active, not recruiting NCT NCT07398261

Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

Not yet reported Menoufia University 151 participants Est. completion 2026-11-01 1 site

Other conditions: Treatment of Non-monosymptomatic Nocturnal Enuresis
View official trial listing →
Completed NCT NCT07447518

Double j Stent Related Symptoms

Not yet reported Kafrelsheikh University 535 participants Est. completion 2023-09-01 1 site

Other conditions: Lower Urinary Tract Symptoms
View official trial listing →
Completed NCT NCT07533565

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

Not yet reported Kafrelsheikh University 78 participants Est. completion 2025-10-01 1 site Stand-alone

Other conditions: Cirrhosis, Asthma
View official trial listing →
Not yet recruiting NCT NCT07566208

Using Mirabegron to Control Arrhythmia-1

Not yet reported Cedars-Sinai Medical Center 20 participants Est. completion 2028-05 Stand-alone

Other conditions: Ventricular Arrhythmias and Cardiac Arrest
View official trial listing →
Completed NCT NCT07566416

MIRABEGRON AND UAS OUTCOMES DURING RIRS

Ankara Training and Research Hospital 131 participants Est. completion 2025-02-10 1 site

Other conditions: Kidney Stone, Retrograde Intrarenal Surgery (RIRS), Ureteral Access Sheath
View official trial listing →
Not yet recruiting NCT NCT07585513

Beta-3 Enhanced Autonomic Therapy for POTS

Not yet reported Cedars-Sinai Medical Center 36 participants Est. completion 2028-05 Stand-alone

Other conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
View official trial listing →
Not yet recruiting NCT NCT07627529

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

Not yet reported Corporal Michael J. Crescenz VA Medical Center 20 participants Est. completion 2027-04 1 site Stand-alone

Other conditions: Parkinson Disease (PD)
View official trial listing →
Completed NCT NCT07668232

Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation

Not yet reported South Valley University 52 participants Est. completion 2025-12-30 1 site

Other conditions: Posterior Urethral Valve
View official trial listing →
Not yet recruiting NCT NCT07711808

Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study

Not yet reported Universidade do Porto 208 participants Est. completion 2027-08

Other conditions: Overactive Bladder (OAB)
View official trial listing →
Completed NCT NCT07736560

Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron

Başakşehir Çam & Sakura City Hospital 40 participants Est. completion 2026-06-30 1 site

Other conditions: Overactive Bladder (OAB), Premature (Early) Ejaculation, Ejaculation Abnormal
View official trial listing →
Not yet recruiting NCT NCT07773532

Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

Bagcilar Training and Research Hospital 115 participants Est. completion 2027-11-01 1 site

Other conditions: Overactive Bladder (OAB)
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT05713799

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.